Updating results

Upadacitinib for treating moderate to severe rheumatoid arthritis [ID1400]: appraisal consultation

We are listening to your views on this technology appraisal guidance. Comments close 21 February 2020.

Technology appraisal guidance In consultation

Lorlatinib for treating ALK-positive advanced non-small-cell lung cancer [ID1338]: appraisal consultation

We are listening to your views on this technology appraisal guidance. Comments close 18 February 2020.

Technology appraisal guidance In consultation

Esketamine for treatment-resistant depression (ID1414): appraisal consultation

We are listening to your views on this technology appraisal guidance. Comments close 18 February 2020.

Technology appraisal guidance In consultation

Pembrolizumab with axitinib for untreated advanced renal cell carcinoma [ID1426]: appraisal consultation

We are listening to your views on this technology appraisal guidance. Comments close 04 March 2020.

Technology appraisal guidance In consultation